GGrantIndex
Sort

30,917 grants matching tumor microenvironment

The role of chronic stress in regulation of mutant p53 and tumorigenesis

$363,306
Wenwei Hu · Rbhs -Cancer Institute Of New Jersey · R01 · FY2020 · CA

Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer

$363,250
Bilal Bin Hafeez · University Of Texas Rio Grande Valley · SC1 · FY2023 · GM

Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer

$363,250
Bilal Bin Hafeez · University Of Texas Rio Grande Valley · SC1 · FY2024 · GM

Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer

$363,250
Bilal Bin Hafeez · University Of Texas Rio Grande Valley · SC1 · FY2022 · GM

Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer

$363,250
Bilal Bin Hafeez · University Of Texas Rio Grande Valley · SC1 · FY2021 · GM

Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy

$363,204
Drew M. Pardoll · Johns Hopkins University · R01 · FY2019 · CA

The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer

$363,165
Don Lynn Gibbons · University Of Tx Md Anderson Can Ctr · R37 · FY2023 · CA

DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS

$363,164
Nicholas Navin · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis

$363,164
Florencia McAllister · University Of Tx Md Anderson Can Ctr · R37 · FY2023 · CA

Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants

$363,164
Juan Fueyo · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Role of SAP30 in hypoxia inducible factor activation and breast cancer progression

$363,164
Weibo Luo · Ut Southwestern Medical Center · R01 · FY2023 · CA

DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS

$363,164
Nicholas Navin · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants

$363,164
Juan Fueyo · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer

$363,164
Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors

$363,164
Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01

$363,164
Melody A Swartz · University Of Chicago · R01 · FY2022 · CA

Toward understanding the role of altered glycosylation in cancer

$363,139
Stacy Alyse Malaker · Yale University · R35 · FY2022 · GM

The role of miRNA15a and 16-1 in Multiple Myeloma

$363,125
Irene M. Ghobrial · Dana-Farber Cancer Inst · R01 · FY2012 · CA

The role of miRNA15a and 16-1 in Multiple Myeloma

$363,125
Irene M. Ghobrial · Dana-Farber Cancer Inst · R01 · FY2015 · CA

The role of miRNA15a and 16-1 in Multiple Myeloma

$363,125
Irene M. Ghobrial · Dana-Farber Cancer Inst · R01 · FY2011 · CA

Reprogramming of the stromal microenvironment in melanoma progression and therapeutic escape

$363,124
Yuhang Zhang · University Of Cincinnati · R01 · FY2025 · CA

FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma

$363,090
Andrew E Aplin · Thomas Jefferson University · R01 · FY2022 · CA

Targeted therapies in cutaneous melanoma

$363,090
Andrew E Aplin · Thomas Jefferson University · R01 · FY2023 · CA

Function of Membrane Type Matrix Metalloproteinase

$363,090
Stephen Weiss · University Of Michigan At Ann Arbor · R01 · FY2022 · CA

Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma

$363,090
Roger S Lo · University Of California Los Angeles · R01 · FY2022 · CA